CLINICAL USE

Treatment of type 2 diabetes mellitus in combination with other antidiabetic drugs

DOSE IN NORMAL RENAL FUNCTION

With metformin or thiazolidinedione: 50 mg twice daily With a sulphonylurea: 50 mg in the morning

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 303.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 9.3
  • %Excreted unchanged in urine &nbsp &nbsp : 23

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 71 litres

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 3/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Avoid
  • 10 to 20 &nbsp &nbsp : Avoid
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Avoid

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Avoid

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Avoid
  • HDF/high flux &nbsp : Not dialysed. Avoid
  • CAV/VVHD &nbsp &nbsp &nbsp: Not dialysed. Avoid

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Use is contraindicated in renal impairment due to lack of data Cases of hepatic dysfunction have occasionally been reported The main metabolite (LAY 151) is removed by haemodialysis .
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt